<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409731</url>
  </required_header>
  <id_info>
    <org_study_id>16-310</org_study_id>
    <nct_id>NCT03409731</nct_id>
  </id_info>
  <brief_title>Absorb GT1 Japan PMS</brief_title>
  <official_title>Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System Post-marketing Surveillance (PMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Surveillance is to know the frequency and status of adverse device effects
      and adverse events in order to assure the safety of the new medical device, and to collect
      efficacy and safety information for evaluating clinical use results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The surveillance consists of two phases as detailed below. All patients will be continuously
      registered in each phases.

      Phase 1 (All- patients): Includes 250 patients (approximately 45 sites)

      Main Purpose: To confirm the efficacy of physician training and to establish optimal training
      for increasing medical institutions participating in post-marketing evaluation. Procedural
      results will be evaluated sequentially for early feedback to the sites. Therefore, there will
      be no quantitative goal established to move to Phase 2. However, recommended procedure may be
      updated as required in order to achieve optimal acute result.

      Phase 2 (All- patients): Until 2000 patients are registered (up to 200 sites) Main Purpose:
      To confirm safety.

      Target sample size of the Surveillance is approximately 2,000 patients. Commercial sale of
      Absorb GT1 beyond the purpose of the Surveillance will be started if the scaffold thrombosis
      (ST) rate in the 2,000 patients at 3 month is 0.9% or lower (ST rates for patients with
      Absorb GT1).

      In the ABSORB III (NCT01751906) clinical trial, 19 events of definite/probable ST reported
      through 1 year, and 18 of them except 1 occurred within 3 months (maximum of 78 days)
      post-procedure. Therefore, it is appropriate to perform interim analysis for the safety using
      ST rate through 3 months. The event occurred after 3 months was reported 362 days after the
      procedure, and the patient stopped treatment with thienopyridine antiplatelet agent on Day
      356.

      Both in the AVJ-301 (NCT01844284) and the ABSORB III clinical trials, ST rate through 1 year
      was 1.5%. In the ABSORB III clinical trial, ST rate in target lesion with Reference Vessel
      Diameter (RVD) ≥ 2.25 mm was 0.9%. As explained above, ST rates at 3 months and 1 year are
      almost similar. The half widths of the 95% confidence intervals (CI) to different sample
      sizes are presented in the table 2.3-1. The half width of 95% CI decreases from 0.6% to 0.4%
      when a sample size is increased from 1,000 to 2,000. However, further increase in the sample
      size does not result in significant decrease in the half width of 95% CI. Therefore, the
      sample size of the Surveillance was established as 2,000 patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2016</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Actual">May 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Acute Scaffold Thrombosis (ST)</measure>
    <time_frame>Day 0</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</measure>
    <time_frame>&gt;1 to 30 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Late Scaffold Thrombosis (ST)</measure>
    <time_frame>31 to 90 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cumulative Scaffold Thrombosis</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Composite of Device Deficiencies</measure>
    <time_frame>During index procedure</time_frame>
    <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies
Lesion/implant failure
Delivery difficulty (finally delivered)
Re-crossing failure
Re-crossing difficulty
Post-dilatation balloon
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)
Instruction for Use (IFU) not included
Major Strut Malapposition
Strut Fracture within 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/Myocardial Infarction (MI)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Myocardial Infarction (MI)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Lesion Revascularization (TLR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Target Vessel Revascularization (TVR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All Coronary Revascularization</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/All Revascularization (DMR)</measure>
    <time_frame>0 to 30 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death/MI/Any Revascularization (DMR)</measure>
    <time_frame>0 to 90 days</time_frame>
    <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <condition>Angina Pectoris</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Occlusion</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Absorb GT1 BVS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ABSORB GT1 BVS</intervention_name>
    <description>Patients receiving Absorb GT1 BVS</description>
    <arm_group_label>Absorb GT1 BVS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General Percutaneous coronary intervention (PCI) population.

        Exclusion Criteria:

          -  No specific exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masato Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toho University Ohashi Medical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya Daini Red Cross Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Tokyo</name>
      <address>
        <city>Matsudo</city>
        <state>Chiba</state>
        <zip>270-2232</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shin Koga Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanaoka Seishu Memorial Cardiovascular Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurashiki Central Hospital</name>
      <address>
        <city>Kurashiki</city>
        <state>Okayama</state>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Sekishinkai</name>
      <address>
        <city>Sayama</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mitsui Memorial Museum</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>101-8643</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teikyo University</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toho University Ohashi Medical Center</name>
      <address>
        <city>Meguro</city>
        <state>Tokyo</state>
        <zip>153-8515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyazaki Medical Association Hospital</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 3, 2019</results_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug eluting Bio-resolvable Scaffold (BRS)</keyword>
  <keyword>Bio-resolvable Scaffold (BRS)</keyword>
  <keyword>Real world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03409731/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT03409731/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This Post-marketing Surveillance study was conducted in patients with ischemic heart disease potentially indicated for treatment with the Absorb GT1 Bioresorbable Vascular Scaffold System. A total of 135 patients were enrolled between December 13, 2016 to December 11, 2017 time period.</recruitment_details>
      <pre_assignment_details>The proposed target sample size of the surveillance was approximately 2,000 patients. However, only 135 patients were registered in this study since Absorb GT1 was withdrawn from global market, due to low sales volume</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dyslipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.25" spread="25.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Myocardial Infarction (MI)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior PCI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Acute Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>Day 0</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>&gt;1 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sub Acute Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>31 to 90 days</time_frame>
        <population>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Late Scaffold Thrombosis (ST)</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2),Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%). Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
        <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cumulative Scaffold Thrombosis</title>
          <description>Criteria: ST rate (in 2,000 patients : sum of Phase 1 and Phase 2), Success Criteria: ST rate at 3 months is ≤ 18 patients (0.9%).
Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points and with the different separate time points. Time 0 is defined as the time point after the guiding catheter has been removed and the subject left the catheterization lab.
Timings:
Acute scaffold/stent thrombosis : 0 - 24 hours post stent implantation Subacute scaffold/stent thrombosis: &gt;24 hours - 30 days post stent implantation Late scaffold/stent thrombosis: 30 days - 1 year post stent implantation Very late scaffold/stent thrombosis: &gt;1 year post stent implantation</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Composite of Device Deficiencies</title>
        <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies
Lesion/implant failure
Delivery difficulty (finally delivered)
Re-crossing failure
Re-crossing difficulty
Post-dilatation balloon
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)
Instruction for Use (IFU) not included
Major Strut Malapposition
Strut Fracture within 6 months</description>
        <time_frame>During index procedure</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite of Device Deficiencies</title>
          <description>Device deficiencies: Number of participants with at least one of the following Device deficiencies
Lesion/implant failure
Delivery difficulty (finally delivered)
Re-crossing failure
Re-crossing difficulty
Post-dilatation balloon
Optical Coherence Tomography (OCT)/Intravascular Ultrasound (IVUS)
Instruction for Use (IFU) not included
Major Strut Malapposition
Strut Fracture within 6 months</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lesion/implant failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Delivery difficulty (finally delivered)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-crossing failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Re-crossing difficulty</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-dilatation balloon+OCT/IVUS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFU not included</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Major Strut Malapposition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Strut Fracture within 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/Myocardial Infarction (MI)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/Myocardial Infarction (MI)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Death (Cardiac, Vascular, Non-Cardiovascular)</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.
Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.
Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death</title>
        <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death</title>
          <description>Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Myocardial Infarction (MI)</title>
        <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Myocardial Infarction (MI)</title>
          <description>Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.
All myocardial infarction includes target vessel myocardial infarction (TV-MI) and not attributable to target vessel myocardial infarction (NTV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
        <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Target Vessel Myocardial Infarction (TV-MI)</title>
          <description>Myocardial infarction attributed to target vessel myocardial infarction (TV-MI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Lesion Revascularization (TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</title>
        <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemic-Driven Target Lesion Revascularization (ID-TLR)</title>
          <description>Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.
The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
        <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Target Vessel Revascularization (TVR)</title>
          <description>Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
        <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ischemia Driven Target Vessel Revascularization (ID-TVR)</title>
          <description>Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself.</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All Coronary Revascularization</title>
        <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All Coronary Revascularization</title>
          <description>Coronary revascularization attributed to either Coronary artery bypass grafting (CABG) or Percutaneous coronary intervention (PCI)</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
        <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cardiac Death/TV-MI/ID-TLR (TLF)</title>
          <description>Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/All Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 30 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/All Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death/MI/Any Revascularization (DMR)</title>
        <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
        <time_frame>0 to 90 days</time_frame>
        <population>Full Analysis Set (all participants with Absorb GT1)</population>
        <group_list>
          <group group_id="O1">
            <title>Absorb GT1 BVS</title>
            <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death/MI/Any Revascularization (DMR)</title>
          <description>DMR is the composite of All Death, All Myocardial infarction (MI) and All Revascularization</description>
          <population>Full Analysis Set (all participants with Absorb GT1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Absorb GT1 BVS</title>
          <description>Patients receiving Absorb GT1 Bioresorbable Vascular Scaffold System.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>GALLSTONE ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>LUNG CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CANCER OF HEAD OF PANCREAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>TLR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hajime Kusano</name_or_title>
      <organization>Abbott medical device</organization>
      <phone>+1 408-845-1626</phone>
      <email>hajime.kusano@abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

